Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 425, Issue 1, 2012, Pages 76-82

  Nicolaou, Katerina A ^a   Liapis, Vasilis ^b   Evdokiou, Andreas ^b   Constantinou, Constantina ^c   Magiatis, Prokopios ^d   Skaltsounis, Alex L ^d   Koumas, Laura ^e   Costeas, Paul A ^e   Constantinou, Andreas I ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF ATHENS   (Greece)

^e Center for Study of Hematological Malignancies   (Cyprus)

Author keywords

Apoptosis; Breast cancer; Cell cycle; Indirubin derivatives

Indexed keywords

6 BROMOINDIRUBIN 3'OXIME; 7 BROMOINDIRUBIN 3'OXIME; ANTINEOPLASTIC ALKALOID; CASPASE 8; CASPASE 9; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER PATIENT; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; UPREGULATION;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; FEMALE; HUMANS; INDOLES; NEOPLASM INVASIVENESS; OXIMES;

EID: 84865186578     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.053     Document Type: Article

References (24)

1. Meijer L., Skaltsounis A.L., Magiatis P., Polychronopoulos P., Knockaert M., Leost M., Ryan X.P., Vonica C.A., Brivanlou A., Dajani R., Crovace C., Tarricone C., Musacchio A., Roe S.M., Pearl L., Greengard P. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 2003, 10:1255-1266.
2. Guengerich F.P., Sorrells J.L., Schmitt S., Krauser J.A., Aryal P., Meijer L. Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis. J. Med. Chem. 2004, 47:3236-3241.
3. Wu Z.L., Aryal P., Lozach O., Meijer L., Guengerich F.P. Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6. Chem. Biodivers 2005, 2:51-65.
4. Adachi J., Mori Y., Matsui S., Takigami H., Fujino J., Kitagawa H., Miller C.A., Kato T., Saeki K., Matsuda T. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. 2001, 276:31475-31478.
5. Xiao Z., Hao Y., Liu B., Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002, 43:1763-1768.
6. Bradbury J. From Chinese medicine to anticancer drugs. Drug Discov. Today 2005, 10:1131-1132.
7. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., Eisenbrand G., Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J. Biol. Chem. 2001, 276:251-260.
8. Ribas J., Bettayeb K., Ferandin Y., Knockaert M., Garrofe-Ochoa X., Totzke F., Schachtele C., Mester J., Polychronopoulos P., Magiatis P., Skaltsounis A.L., Boix J., Meijer L. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death. Oncogene 2006, 25:6304-6318.
9. Ferandin Y., Bettayeb K., Kritsanida M., Lozach O., Polychronopoulos P., Magiatis P., Skaltsounis A.L., Meijer L. 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. J. Med. Chem. 2006, 49:4638-4649.
10. Vougogiannopoulou K., Ferandin Y., Bettayeb K., Myrianthopoulos V., Lozach O., Fan Y., Johnson C.H., Magiatis P., Skaltsounis A.L., Mikros E., Meijer L. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. J. Med. Chem. 2008, 51:6421-6431.
11. Ribas J., Yuste V.J., Garrofe-Ochoa X., Meijer L., Esquerda J.E., Boix J. 7-Bromoindirubin-3'-oxime uncovers a serine protease-mediated paradigm of necrotic cell death. Biochem. Pharmacol. 2008, 76:39-52.
12. Yoneda T., Williams P.J., Hiraga T., Niewolna M., Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J. Bone Miner Res. 2001, 16:1486-1495.
13. M. Thai le, A. Labrinidis, S. Hay, V. Liapis, S. Bouralexis, K. Welldon, B. J. Coventry, D. M. Findlay, and A. Evdokiou, Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model, Cancer Res 66 (2006) 5363-5370.
14. Evdokiou A., Bouralexis S., Atkins G.J., Chai F., Hay S., Clayer M., Findlay D.M. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int. J. Cancer 2002, 99:491-504.
15. Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 2002, 296:1634-1635.
16. Pistritto G., Puca R., Nardinocchi L., Sacchi A., D'Orazi G. HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. Cell Death Differ. 2007, 14:1837-1839.
17. Liu X., Yue P., Khuri F.R., Sun S.Y. P53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004, 64:5078-5083.
18. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 2002, 19:607-614.
19. Datto M.B., Yu Y., Wang X.F. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 1995, 270:28623-28628.
20. Datto M.B., Li Y., Panus J.F., Howe D.J., Xiong Y., Wang X.F. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 1995, 92:5545-5549.
21. Pouliot F., Labrie C. Role of Smad1 and Smad4 proteins in the induction of p21WAF1, Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J. Endocrinol. 2002, 172:187-198.
22. Archambault V., Glover D.M. Polo-like kinases: conservation and divergence in their functions and regulation. Nat. Rev. Mol. Cell Biol. 2009, 10:265-275.
23. Y. J. Seo, B. S. Kim, S. Y. Chun, Y. K. Park, K. S. Kang, and T. G. Kwon, Apoptotic Effects of Genistein, Biochanin-A and Apigenin on LNCaP and PC-3 Cells by p21 through Transcriptional Inhibition of Polo-like Kinase-1, J. Korean Med. Sci. 26 1489-1494.
24. Flatt P.M., Tang L.J., Scatena C.D., Szak S.T., Pietenpol J.A. P53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol. Cell Biol. 2000, 20:4210-4223.